Find clinical trials for Non-Hodgkin Lymphoma in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Hodgkin Lymphoma trials near Paris, Île-de-France, FRA:
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Paris 10, France and 66 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Paris, France and 89 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Paris, France and 73 other locations
to define the recommended dose for phase 2 for the combination.The study is focused on patients with relapsed or refractory aggressive B-cell non...
Phase 1
Paris, Cedex 10, France and 17 other locations
intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to...
Phase 1, Phase 2
Paris, Ile De France, France and 8 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Paris Cedex 10, France and 55 other locations
or unresectable solid tumors and relapsed and/or refractory advanced Non-Hodgkin's lymphoma (NHL). The dose escalation par...
Phase 1
Villejuif, France and 10 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
Paris, Ile-de-France, France and 74 other locations
of BCL6 (BCL6 LDD), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin...
Phase 1, Phase 2
Villejuif, Paris, France and 18 other locations
study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non...
Phase 2
Villejuif Cedex, France and 16 other locations
Clinical trials
Research sites
Resources
Legal